|
1
|
Zhao XF and Gartenhaus RB: Phospho-p70S6K
and cdc2/cdk1 as therapeutic targets for diffuse large B-cell
lymphoma. Expert Opin Ther Targets. 13:1085–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu P, Kao TP and Huang H: CDK1 promotes
cell proliferation and survival via phosphorylation and inhibition
of FOXO1 transcription factor. Oncogene. 27:4733–4744. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pérez de Castro I, de Cárcer G and
Malumbres M: A census of mitotic cancer genes: New insights into
tumor cell biology and cancer therapy. Carcinogenesis. 28:899–912.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tripathi A and Chaube SK: Reduction of
phosphorylated Thr-161 Cdk1 level participates in
roscovitine-induced Fas ligand-mediated apoptosis in rat eggs
cultured in vitro. In Vitro Cell Dev Biol Anim. 51:174–182. 2015.
View Article : Google Scholar
|
|
6
|
Gray NS, Wodicka L, Thunnissen AM, Norman
TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L,
et al: Exploiting chemical libraries, structure, and genomics in
the search for kinase inhibitors. Science. 281:533–538. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mori Y, Inoue Y, Taniyama Y, Tanaka S and
Terada Y: Phosphorylation of the centrosomal protein, Cep169, by
Cdk1 promotes its dissociation from centrosomes in mitosis. Biochem
Biophys Res Commun. 468:642–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iizuka D, Inanami O, Kashiwakura I and
Kuwabara M: Purvalanol A enhances cell killing by inhibiting
up-regulation of CDC2 kinase activity in tumor cells irradiated
with high doses of X rays. Radiat Res. 167:563–571. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ,
Chang KY, Liang SS, Tsai CJ and Shiue YL: Overexpression of
stathmin 1 confers an independent prognostic indicator in
nasopharyngeal carcinoma. Tumour Biol. 35:2619–2629. 2014.
View Article : Google Scholar
|
|
10
|
Baquero MT, Hanna JA, Neumeister V, Cheng
H, Molinaro AM, Harris LN and Rimm DL: Stathmin expression and its
relationship to microtubule-associated protein tau and outcome in
breast cancer. Cancer. 118:4660–4669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akhtar J, Wang Z, Jiang WP, Bi MM and
Zhang ZP: Stathmin overexpression identifies high risk for
lymphatic metastatic recurrence in pN0 esophageal squamous cell
carcinoma patients. J Gastroenterol Hepatol. 29:944–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wegiel B, Wang Y, Li M, Jernigan F and Sun
L: Novel indolyl-chalcones target stathmin to induce cancer cell
death. Cell Cycle. 15:1288–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yip YY, Yeap YY, Bogoyevitch MA and Ng DC:
Differences in c-Jun N-terminal kinase recognition and
phosphorylation of closely related stathmin-family members. Biochem
Biophys Res Commun. 446:248–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Y, Liu C, Xu YF, Cheng H, Shi S, Wu CT
and Yu XJ: Stathmin destabilizing microtubule dynamics promotes
malignant potential in cancer cells by epithelial-mesenchymal
transition. Hepatobiliary Pancreat Dis Int. 13:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akhtar J, Wang Z, Yu C, Li CS, Shi YL and
Liu HJ: STMN-1 is a potential marker of lymph node metastasis in
distal esophageal adenocarcinomas and silencing its expression can
reverse malignant phenotype of tumor cells. BMC Cancer. 14:282014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin X, Liu S, Luo X, Ma X, Guo L, Li L, Li
Z, Tao Y and Cao Y: EBV-encoded LMP1 regulates Op18/stathmin
signaling pathway by cdc2 mediation in nasopharyngeal carcinoma
cells. Int J Cancer. 124:1020–1027. 2009. View Article : Google Scholar
|
|
17
|
Lin X, Liao Y, Xie J, Liu S, Su L and Zou
H: Op18/stathmin is involved in the resistance of Taxol among
different epithelial carcinoma cell lines. Cancer Biother
Radiopharm. 29:376–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin X, Liao Y, Chen X, Long D, Yu T and
Shen F: Regulation of oncoprotein 18/stathmin signaling by ERK
concerns the resistance to Taxol in nonsmall cell lung cancer
cells. Cancer Biother Radiopharm. 31:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laurie SA, Solomon BJ, Seymour L, Ellis
PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge
F, et al: Randomised, double-blind trial of carboplatin and
paclitaxel with daily oral cediranib or placebo in patients with
advanced non-small cell lung cancer: NCIC Clinical Trials Group
study BR29. Eur J Cancer. 50:706–712. 2014. View Article : Google Scholar
|
|
20
|
Wang T, Lv JH, Zhang XF, Li CJ, Han X and
Sun YJ: Tissue inhibitor of metalloproteinase-1 protects MCF-7
breast cancer cells from paclitaxel-induced apoptosis by decreasing
the stability of cyclin B1. Int J Cancer. 126:362–370. 2010.
View Article : Google Scholar
|
|
21
|
Feng W, Xiaoyan X, Xuan Y, Xiangke L,
Zichang Y, Ran Z, Liuxing W and Qingxia F: Silencing
stathmin-modulating efficiency of chemotherapy for esophageal
squamous cell cancer with paclitaxel. Cancer Gene Ther. 22:115–121.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yared JA and Tkaczuk KH: Update on taxane
development: New analogs and new formulations. Drug Des Devel Ther.
6:371–384. 2012.PubMed/NCBI
|
|
23
|
Chen LK, Liang Y, Yang QY, Xu F, Zhou NN,
Xu GC, Liu GZ and Wei WD: Triplet platinum-based combination
sequential chemotherapy improves survival outcome and quality of
life of advanced non-small cell lung cancer patients. Asian Pac J
Cancer Prev. 13:1863–1867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee HH, Ye S, Li XJ, Lee KB, Park MH and
Kim SM: Combination treatment with paclitaxel and doxorubicin
inhibits growth of human esophageal squamous cancer cells by
inactivation of Akt. Oncol Rep. 31:183–188. 2014.
|
|
25
|
Kang J, Sergio CM, Sutherland RL and
Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not
CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast
cancer cells. BMC Cancer. 14:322014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hayashi T, Adachi K, Ohba S and Hirose Y:
The Cdk inhibitor flavopiridol enhances temozolomide-induced
cytotoxicity in human glioma cells. J Neurooncol. 115:169–178.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng F, Bhupathi D, Sun JD, Liu Q,
Ahluwalia D, Wang Y, Matteucci MD and Hart CP: Enhancement of
hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1
inhibition. BMC Cancer. 15:4222015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Balasubramani M, Nakao C, Uechi GT,
Cardamone J, Kamath K, Leslie KL, Balachandran R, Wilson L, Day BW
and Jordan MA: Characterization and detection of cellular and
proteomic alterations in stable stathmin-overexpressing,
Taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE
difference gel electrophoresis. Mutat Res. 722:154–164. 2011.
View Article : Google Scholar :
|
|
29
|
Chen PW, Lin SJ, Tsai SC, Lin JH, Chen MR,
Wang JT, Lee CP and Tsai CH: Regulation of microtubule dynamics
through phosphorylation on stathmin by Epstein-Barr virus kinase
BGLF4. J Biol Chem. 285:10053–10063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han ZX, Wang HM, Jiang G, Du XP, Gao XY
and Pei DS: Overcoming paclitaxel resistance in lung cancer cells
via dual inhibition of stathmin and Bcl-2. Cancer Biother
Radiopharm. 28:398–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin X, Tang M, Tao Y, Li L, Liu S, Guo L,
Li Z, Ma X, Xu J and Cao Y: Epstein-Barr virus-encoded LMP1
triggers regulation of the ERK-mediated Op18/stathmin signaling
pathway in association with cell cycle. Cancer Sci. 103:993–999.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He H, Sun YP, Zheng L and Yue ZG:
Steroidal saponins from Paris polyphylla induce apoptotic cell
death and autophagy in A549 human lung cancer cells. Asian Pac J
Cancer Prev. 16:1169–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu Y, Tang M, Wu Y, Weng X, Yang L, Xu W,
Yi W, Gao J, Bode AM, Dong Z, et al: A combination of paclitaxel
and siRNA-mediated silencing of Stathmin inhibits growth and
promotes apoptosis of nasopharyngeal carcinoma cells. Cell Oncol
(Dordr). 37:53–67. 2014. View Article : Google Scholar
|
|
34
|
Xi Q, Huang M, Wang Y, Zhong J, Liu R, Xu
G, Jiang L, Wang J, Fang Z and Yang S: The expression of CDK1 is
associated with proliferation and can be a prognostic factor in
epithelial ovarian cancer. Tumour Biol. 36:4939–4948. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang JQ, Liu HX, Liang Z, Sun YM and Wu M:
Over-expression of p53, p21 and Cdc2 in histologically negative
surgical margins is correlated with local recurrence of laryngeal
squamous cell carcinoma. Int J Clin Exp Pathol. 7:4295–4302.
2014.PubMed/NCBI
|
